Enlivex Ltd. (ENLV) operates as a small, clinical-stage biotechnology firm centered on macrophage reprogramming. Macrophages serve as key white blood cells in the immune response to infection, injury, and disease. The core concept here involves situations where these cells shift into an overactive, harmful state, and the aim is to bring them back to a balanced condition to address underlying issues. I follow ENLV due to its focus on sizable markets with limited options, though it remains a high-risk, pre-revenue name in biotech.
Founded in 2005 and based in Ness Ziona, Israel, Enlivex trades on the NASDAQ Capital Market without any marketed products or product revenue to date. Its efforts revolve around the Allocetra platform, an allogeneic cell therapy produced from healthy donor cells. This off-the-shelf approach allows storage and administration without patient-specific customization, setting it apart from many personalized options. The therapy seeks to return macrophages to homeostasis, targeting inflammation and immune imbalance at the source rather than just easing symptoms.
Development spans several areas, with the most advanced work in knee osteoarthritis, a widespread condition where disease-modifying treatments are still scarce. Additional programs address organ dysfunction from sepsis and earlier efforts in TMJ osteoarthritis plus solid tumors. A prior collaboration with BeiGene explored Allocetra alongside an immune checkpoint inhibitor in advanced solid tumors. Funding has come mainly from equity and debt raises, with spending centered on R&D. The off-the-shelf model offers a potential edge in scalability, though competition includes larger players with broader resources.
Attention centers on the substantial unmet needs in target markets and the technology's possible differentiation. Osteoarthritis affects millions globally, with most therapies focused on symptom relief instead of changing disease progression. A treatment that could modify the course would open a meaningful opportunity. Sepsis drives many hospital deaths with few targeted options available, so a macrophage-focused method to resolve immune dysfunction could mark a notable step forward. The manufacturing approach may also prove more practical for broader use than individualized therapies.
As a smaller company with a concentrated pipeline, the stock reacts strongly to clinical updates, regulatory news, and financing activity. One notable point is the Regenerative Medicine Advanced Therapy designation from the FDA for Allocetra in age-related knee osteoarthritis, which can help accelerate development and review.
Investing in ENLV involves notable binary risks common to clinical-stage biotechs. No products are approved, revenue is absent, and outcomes rest almost entirely on trial results. Unfavorable data could shift the outlook substantially. Most experimental therapies do not reach the market, and approval is never assured. Larger competitors with more resources add pressure, and reliance on capital markets for funding can lead to dilution. The modest team size and single-platform focus tie performance closely to one technology, making this a speculative holding suited mainly to those comfortable with volatility.
When evaluating names like this, I often run quick comparisons through Tickeron’s AI Screener to check how ENLV stacks up against peers on key metrics and patterns. It helps surface context without replacing deeper due diligence.
Enlivex Ltd. (ENLV) stands out in biotech through its macrophage-reprogramming focus and off-the-shelf cell therapy platform. Allocetra targets sizable areas with clear needs, such as knee osteoarthritis and sepsis-related complications. Still, as a pre-revenue clinical-stage entity, its path depends on trial results, regulatory steps, and capital access. This makes it a name of interest for those following emerging immunotherapies while accepting the associated risks.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
On November 18, 2026, the Stochastic Oscillator for ENLV moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 57 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENLV entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.006) is normal, around the industry mean (3.596). P/E Ratio (0.001) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions
Industry Biotechnology